Clinical Trials
320 trialsSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
MK-3475-06B
Merck Sharp & Dohme LLC
MK-3475-06C
Merck Sharp & Dohme LLC
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
University of Pittsburgh
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
OHSU Knight Cancer Institute
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NEXUS-01
Eli Lilly and Company
Registry for Esophageal and Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
FiREBOLT
Eli Lilly and Company
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
M.D. Anderson Cancer Center
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Tianjin Medical University Cancer Institute and Hospital
PIONEER
University of Utah
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
Exercise Training After Upper Gastrointestinal Cancer Surgery
Kansai Medical University
The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Jinling Hospital, China
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shanghai Henlius Biotech
Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer
Region Skane
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
DG-03
AstraZeneca
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
FREJENO
University Hospital, Bordeaux
MK-3475-06D
Merck Sharp & Dohme LLC
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Central South University
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Alliance for Clinical Trials in Oncology
PALEO
Australasian Gastro-Intestinal Trials Group
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
panSOHO
Bayer
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
SISTER
University Medical Center Groningen
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
Zhejiang University
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
DP-04
AstraZeneca
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
VALUE
University Hospital Southampton NHS Foundation Trust
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer
Semmelweis University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Pfizer